A Proof of Concept Study to Assess the Safety and IOP-Lowering Effect of AL-59412C Injected Intravitreally

Trial Profile

A Proof of Concept Study to Assess the Safety and IOP-Lowering Effect of AL-59412C Injected Intravitreally

Discontinued
Phase of Trial: Phase II

Latest Information Update: 27 Oct 2015

At a glance

  • Drugs AL 59412C (Primary) ; Travoprost
  • Indications Ocular hypertension; Open-angle glaucoma
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Alcon
  • Most Recent Events

    • 27 Oct 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top